CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Wall Street analysts forecast CUE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CUE is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cue Biopharma Inc revenue for the last quarter amounts to 2.15M USD, decreased -35.58 % YoY.

Cue Biopharma Inc. EPS for the last quarter amounts to -0.07 USD, decreased -58.82 % YoY.

Cue Biopharma Inc (CUE) has 41 emplpoyees as of January 10 2026.

Today CUE has the market capitalization of 32.89M USD.